All Comparisons
Tirzepatide vs Cagrilintide
Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.
Tirzepatide: ACagrilintide: B
| Attribute | Tirzepatide | Cagrilintide |
|---|---|---|
| Category | Metabolic / Dual GIP-GLP-1 Agonist | Metabolic / Amylin Analog |
| Evidence Rating | A — FDA Approved | B — Phase III / NDA Filed |
| Clinical Status | FDA-approved (Mounjaro for T2D, Zepbound for obesity and OSA) | Phase 3 (REDEFINE program). NDA filed with FDA in 2026 for CagriSema. |
| Mechanism | Tirzepatide (MW ~4813 g/mol, C225H348N48O68) simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual agonism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, increases satiety ... | Cagrilintide activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and other hindbrain regions, promoting meal-related satiety through distinct pathways from GLP-1 agonism. It slows gastric emptying, suppresses inappropriate glucagon release, and activates central ap... |
| Half-Life | ~5 days (116 hours) | ~7 days (allows once-weekly dosing) |
| Bioavailability | ~80% SC | SC injection |
| Molecular Weight | ~4813.5 g/mol | — |
| WADA Status | Not Prohibited | Not Listed |
| Research Half-Life | ~5 days (116 hours) | ~7 days (allows once-weekly dosing) |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | FDA-approved: Mounjaro (T2D, adults and children 10+) and Zepbound (obesity/overweight with comorbidities, severe OSA including new sleep apnea approval). Compounding fully prohibited for 503B facilities. Prescription only. | Not yet FDA-approved. NDA filed by Novo Nordisk in 2026 for CagriSema (cagrilintide + semaglutide) for chronic weight management. FDA review expected 2026-2027. |
Research Material Specifications
Catalog specifications for the corresponding research materials, including batch documentation coverage.
| Specification | Tirzepatide | Cagrilintide |
|---|---|---|
| Purity Standard | ≥98% | ≥98% |
| CAS Number | 2023788-19-2 | N/A |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ | N/A |
| Available Formats | 10mg, 30mg | 10mg |
| Batch COAs Published | — | — |
| Stock Status | In stock | Out of stock |
Availability at Volta Peptides
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.